Rexahn Pharmaceuticals announced that it has completed patient enrollment in its Phase 2a trial evaluating the effectiveness of Serdaxin as a treatment for major depressive disorder (MDD). This study is a randomized, double blind, placebo-controlled and dose ranging study enrolling 75 patients and is being conducted at multiple sites in the United States with preliminary findings anticipated in late 2009. The primary efficacy endpoint is the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS).
Serdaxin is a dual serotonin and dopamine enhancer being evaluated as a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses.
For more information call (240) 268-5300 or visit www.rexahn.com.